{
  "generated_at": "2026-02-06T11:00:33.855054",
  "market_temperature": {
    "temperature": "HOT",
    "market_pe": 27.469559,
    "interpretation": "Market P/E of 27.5 is elevated. Few bargains, consider holding cash.",
    "checked_at": "2026-02-06T10:59:58.745306"
  },
  "summary": {
    "total_analyzed": 3,
    "buy_candidates": 0,
    "watchlist": 1,
    "bubble_warnings": 4,
    "radar": 10
  },
  "portfolio": {
    "positions": [],
    "position_count": 0,
    "total_invested": 0,
    "current_value": 0,
    "total_gain_loss": 0,
    "total_gain_loss_pct": 0,
    "sector_exposure": {},
    "sector_warnings": [],
    "performance": {
      "total_trades": 0,
      "winning_trades": 0,
      "losing_trades": 0,
      "win_rate": 0
    }
  },
  "performance": {
    "total_trades": 0,
    "winning_trades": 0,
    "losing_trades": 0,
    "win_rate": 0
  },
  "top_picks": [],
  "watchlist": [
    {
      "symbol": "BCRX",
      "company_name": "BCRX",
      "recommendation": "WATCHLIST",
      "quantitative": {
        "current_price": 6.24,
        "market_cap": 0,
        "pe_ratio": null,
        "debt_equity": null,
        "roe": null,
        "revenue_growth": null
      },
      "valuation": {
        "symbol": "BCRX",
        "current_price": 6.24,
        "average_fair_value": 21.66667,
        "margin_of_safety": 0.7120000443076855,
        "upside_potential": 2.472222756410256,
        "estimates": [
          {
            "source": "Yahoo Finance Analyst Target",
            "fair_value": 21.66667,
            "methodology": "Analyst Price Targets"
          }
        ]
      },
      "qualitative": {
        "symbol": "BCRX",
        "company_name": "BCRX",
        "moat": {
          "rating": "narrow",
          "sources": [
            "Regulatory barriers (FDA approvals)",
            "Patent protection on approved drugs",
            "Specialized R&D capabilities in rare diseases"
          ],
          "explanation": "Pharmaceutical companies can develop narrow moats through patent-protected drugs and regulatory exclusivity, but these advantages are typically time-limited and require constant innovation to maintain."
        },
        "management": {
          "rating": "poor",
          "notes": "Rating: UNABLE TO ASSESS\nNotes: Without access to recent filings, I cannot evaluate management's capital allocation decisions, communication with shareholders, or track record of execution.\nInsider Ownership: Unknown",
          "insider_ownership": null
        },
        "business_summary": "BioCryst Pharmaceuticals is a biotechnology company focused on developing treatments for rare diseases, particularly hereditary angioedema and other complement-mediated diseases. The company generates revenue primarily through drug sales and licensing agreements.",
        "competitive_position": "Operating in the rare disease pharmaceutical space, BCRX faces competition from larger pharmaceutical companies with greater resources. The rare disease market offers opportunities for premium pricing but requires significant R&D investment and regulatory expertise.",
        "risks": {
          "key_risks": [
            "Drug development failure risk - clinical trials may not succeed",
            "Regulatory risk - FDA approval uncertainty",
            "Patent cliff risk - loss of exclusivity on key products"
          ],
          "thesis_risks": [
            "Major clinical trial failure for lead drug candidates",
            "Generic competition significantly earlier than expected due to patent challenges",
            "Severe adverse events leading to FDA warnings or drug withdrawals"
          ]
        },
        "investment_thesis": "Without current financial data, I cannot formulate a proper investment thesis. Any biotech investment requires thorough analysis of pipeline assets, cash runway, and competitive positioning.",
        "conviction_level": "LOW"
      },
      "position_size": {
        "conviction": "LOW",
        "recommended_pct": 0.06,
        "recommended_amount": 3000.0,
        "max_pct": 0.15,
        "max_amount": 7500.0,
        "reasoning": "LOW conviction = 6% allocation ($3,000)"
      },
      "generated_at": "2026-02-06T11:00:32.944232"
    }
  ],
  "radar": [
    "CRUS",
    "PLAB",
    "ACLS",
    "ACAD",
    "ALKS",
    "DIN",
    "FIZZ",
    "AX",
    "SFBS",
    "RRC"
  ],
  "bubble_watch": [
    {
      "symbol": "NET",
      "company_name": "Cloudflare, Inc.",
      "current_price": 163.05,
      "signals": [
        "Extreme P/E of 138 - priced for perfection",
        "High debt/equity of 2.6",
        "Price/Sales of 28 - extremely speculative"
      ],
      "signal_count": 3,
      "risk_level": "HIGH",
      "metrics": {
        "pe_ratio": 137.964,
        "revenue_growth": 0.307,
        "insider_selling": "0 sells, 0 buys recently",
        "debt_change": 2.59964
      },
      "summary": "\u26a0\ufe0f 3 warning signals detected. Valuation appears disconnected from fundamentals. Insiders are selling. "
    },
    {
      "symbol": "TSLA",
      "company_name": "Tesla, Inc.",
      "current_price": 397.21,
      "signals": [
        "P/E of 371 with only -3% revenue growth",
        "Extreme P/E of 371 - priced for perfection"
      ],
      "signal_count": 2,
      "risk_level": "MEDIUM",
      "metrics": {
        "pe_ratio": 371.22427,
        "revenue_growth": -0.031,
        "insider_selling": "0 sells, 0 buys recently",
        "debt_change": null
      },
      "summary": "\u26a0\ufe0f 2 warning signals detected. Valuation appears disconnected from fundamentals. Insiders are selling. "
    },
    {
      "symbol": "PLTR",
      "company_name": "Palantir Technologies Inc.",
      "current_price": 130.01,
      "signals": [
        "Extreme P/E of 210 - priced for perfection",
        "Price/Sales of 69 - extremely speculative"
      ],
      "signal_count": 2,
      "risk_level": "MEDIUM",
      "metrics": {
        "pe_ratio": 209.69354,
        "revenue_growth": 0.7,
        "insider_selling": "0 sells, 0 buys recently",
        "debt_change": null
      },
      "summary": "\u26a0\ufe0f 2 warning signals detected. Valuation appears disconnected from fundamentals. Insiders are selling. "
    },
    {
      "symbol": "RBLX",
      "company_name": "Roblox Corporation",
      "current_price": 60.57,
      "signals": [
        "No earnings (negative P/E) with $43B market cap",
        "High debt/equity of 4.5"
      ],
      "signal_count": 2,
      "risk_level": "MEDIUM",
      "metrics": {
        "pe_ratio": -55.854744,
        "revenue_growth": 0.48,
        "insider_selling": "0 sells, 0 buys recently",
        "debt_change": 4.52128
      },
      "summary": "\u26a0\ufe0f 2 warning signals detected. Insiders are selling. "
    }
  ]
}